Frontline Bioventures Closes Second China RMB Life Science Fund

Frontline Bioventures, a China focused life science investor, has closed its second RMB fund, according to media reports. Frontline has not disclosed the amount of funds raised, as seems to be its habit, but Founder and Managing Partner Leon Chen did tell BioCentury the firm's second RMB fund was twice as big as its first (also not disclosed). Further, he said the firm now has $435 million under management, including the two RMB funds and a US dollar fund. Frontline, headquartered in Shanghai, also has offices in Hong Kong, Suzhou and San Francisco.